HIV-1 promotes renal tubular epithelial cell protein synthesis: Role of mTOR pathway

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Rehman, Shabina ^a   Husain, Mohammad ^a   Yadav, Anju ^a   Kasinath, Balakuntalam S ^b   Malhotra, Ashwani ^a   Singhal, Pravin C ^a  

^a North Shore LIJ Health System ^*  (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LAMININ; FIBRONECTIN; INITIATION FACTOR 2; LAMININ; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; RIBOSOME DNA; S6 KINASE; UNCLASSIFIED DRUG; DNA; ELONGATION FACTOR 2; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR UBF;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL GROWTH; CONTROLLED STUDY; DNA SYNTHESIS; DNA TRANSCRIPTION; EPITHELIUM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; KIDNEY TUBULE EPITHELIUM; MOUSE; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RNA TRANSLATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; DRUG EFFECT; ENZYME ACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRACELLULAR SPACE; KIDNEY TUBULE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY;

EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA; MUS MUSCULUS;

AIDS-ASSOCIATED NEPHROPATHY; ANIMALS; DNA; ENZYME ACTIVATION; EPITHELIAL CELLS; FIBRONECTINS; HIV-1; HUMANS; INTRACELLULAR SPACE; KIDNEY TUBULES; LAMININ; MICE; MODELS, BIOLOGICAL; PEPTIDE ELONGATION FACTOR 2; PHOSPHORYLATION; POL1 TRANSCRIPTION INITIATION COMPLEX PROTEINS; PROTEIN BIOSYNTHESIS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84855476715     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030071     Document Type: Article

References (49)

1. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, et al. (2004) The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 66: 1145-52.
2. Wyatt CM, Klotman PE, D'Agati VD, (2008) HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol 28: 513-22.
3. Tao Y, Kim J, Schrier RW, Edelstein CL, (2005) Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46-51.
4. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, et al. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466-71.
5. Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, et al. (2009) Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol 297 (6): F1597-605.
6. Lieberthal W, Levine JS, (2009) The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease. J Am Soc Nephrol 20: 2493-502.
7. Kumar D, Konkimalla S, Yadav A, Satranatarajan K, Kasinath BS, et al. (2010) HIV-associated Nephropathy: Role of mTOR Pathway. Am J. Pathology 177: 813-21.
8. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
9. Kasinath BS, Feliers D, Sataranatarajan K, Ghosh Choudhury G, Lee MJ, et al. (2009) Regulation of mRNA translation in renal physiology and disease. Am J Physiol Renal Physiol 297: F1153-65.
10. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Feliers D, (2006) mRNA translation: unexplored territory in renal science. J Am Soc Nephrol 2006, 17: 3281-92.
11. Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, et al. (2009) The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun 384: 471-5.
12. Yang Y, Wang J, Qin L, Shou Z, Zhao J, et al. (2007) Wang H, Chen Y, Chen J. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 27: 495-502.
13. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, et al. (2005) Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16: 2063-72.
14. Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu F, et al. (2008) The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron Exp Nephrol 108: e45-56.
15. Weir MR, Wali RK, (2009) Optimizing immunosuppression with sirolimus in the first year posttransplantation: experience in the United States. Transplant Proc 41 (6 Suppl): S13-7.
16. Wolf G, Neilson EG, (1994) Isoproterenol induces mitogenesis in MCT and LLC-PK1 tubular cells. J Am Soc Nephrol 4 (12): 1995-2002.
17. Husain M, Meggs LG, Vashistha H, Simoes S, Griffiths KO, et al. (2009) Inhibition of p66ShcA longevity gene rescues podocytes from HIV-1-induced oxidative stress and apoptosis. J Biol Chem 284: 16648-58.
18. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, et al. (2007) Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol 171: 1733-42.
19. Mariappan MM, D'Silva K, Lee MJ, Sataranatarajan K, Barnes JL, et al. (2011) Ribosomal biogenesis induction by high glucose requires activation of upstream binding factor in kidney glomerular epithelial cells. Am J Physiol Renal Physiol 300: F219-30.
20. Hannan KM, Brandenburger Y, Jenkins A, Sharkey K, Cavanaugh A, et al. (2003) mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol 23: 8862-77.
21. Raught B, Peiretti F, Gingras AC, Livingstone M, Shahbazian D, et al. (2004) Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 23: 1761-9.
22. Scott BA, Avidan MS, Crowder CM, (2002) Regulation of hypoxic death in C. elegans by the insulin/IgF receptor homolog daf-2. Science 296: 2388-2391.
23. Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, et al. (2004) Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by akt. Oncogene 23: 5781-5791.
24. Lamitina ST, Strange K, (2005) Transcriptional targets of daf-16 insulin signaling pathway protect C. elegans from extreme hypertonic stress. Am J Physiol Cell Physiol 288: C467-C474.
25. Patel PH, Tamanoi F, (2006) Increased rheb-tor signaling enhances sensitivity of the whole organism to oxidative stress. J Cell Sci 119: 4285-4292.
26. Nairn AC, Matsushita M, Nastiuk K, Horiuchi A, Mitsui K, et al. (2001) Elongation factor-2 phosphorylation and the regulation of protein synthesis by calcium. Prog Mol Subcell Biol 27: 91-129.
27. Brenner BM, Mackenzie HS, (1997) Nephron mass as a risk factor for progression of renal disease. Kidney Int Suppl 63: S124-7.
28. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, et al. (2006) Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 340: 296-301.
29. Yang Y, Wang J, Qin L, Shou Z, Zhao J, et al. (2007) Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 27: 495-502.
30. Chen JK, Chen J, Neilson EG, Harris RC, (2005) Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 16: 1384-91.
31. Chen JK, Chen J, Thomas G, Kozma SC, Harris RC, (2009) S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 297: F585-93.
32. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, et al. (2006) Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 69: 2029-36.
33. Reddy PS, Legault HM, Sypek JP, Collins MJ, Goad E, et al. (2008) Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis. Arthritis Res Ther 10: R127.
34. Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu F, et al. (2008) The mTOR inhibitor everolimus attenuates the time course of chronic anti-thy1 nephritis in the rat. Nephron Exp Nephrol 108: e45-e56.
35. Kramer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, et al. (2008) Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 294: F440-F449.
36. Bijian K, Cybulsky AV, (2005) Stress proteins in glomerular epithelial cell injury. Contrib Nephrol. Basel, Karger 148: 8-20.
37. Cybulsky AV, Takano T, Papillon J, Bijian K, (2005) Role of the endoplasmic reticulum unfolded protein response in glomerular epithelial cell injury. J Biol Chem 280: 24396-24403.
38. Cybulsky AV, Takano T, Papillon J, Khadir A, Liu J, et al. (2002) Complement c5b-9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells. J Biol Chem 277: 41342-41351.
39. Wolf G, Ziyadeh FN, (1999) Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56: 393-405.
40. Ha H, Hwang IA, Park JH, Lee HB, (2008) Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 82 (suppl 1): S42-S45.
41. Lindenmeyer MT, Rastaldi MP, Ikehata M, Neusser MA, Kretzler M, et al. (2008) Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J Am Soc Nephrol 19: 2225-2236.
42. Inagi R, (2009) Endoplasmic reticulum stress in the kidney as a novel mediator of kidney injury. Nephron Exp Nephrol 112: e1-e9.
43. Roy J, Paquette JS, Fortin JF, Tremblay MJ, (2002) The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 46: 3447-55.
44. Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, et al. (2008) Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci U S A 105: 20476-81.
45. Nicoletti F, Fagone P, Meroni P, McCubrey J, Bendtzen K, (2011) mTOR as a multifunctional therapeutic target in HIV infection. Drug Discov Today 16: 715-21.
46. Nicoletti F, Lapenta C, Donati S, Spada M, Ranazzi A, et al. (2009) Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. Clin Exp Immunol 155: 28-34.
47. Di Benedetto F, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, et al. (2010) First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation 89: 733-8.
48. Redpath NT, Price NT, Proud CG, (1996) Cloning and expression of cDNA encoding protein synthesis elongation factor-2 kinase. J Biol Chem 271: 17547-54.
49. Redpath NT, Foulstone EJ, Proud CG, (1996) Regulation of translation elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway. EMBO J 15: 2291-7.